Skip to Content
Merck
All Photos(1)

Documents

Y0001576

Oxcarbazepine

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

10,11-Dihydro-10-oxo-5h-dibenz[b,f]azepine-5-carboxamide, Oxacarbazepine

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C15H12N2O2
CAS Number:
28721-07-5
Molecular Weight:
252.27
MDL number:
MFCD00865307
UNSPSC Code:
41116107
PubChem Substance ID:
329831491
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

oxcarbazepine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O=C1CC2=C(C=CC=C2)N(C(N)=O)C3=CC=CC=C31

InChI

1S/C15H12N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8H,9H2,(H2,16,19)

InChI key

CTRLABGOLIVAIY-UHFFFAOYSA-N

Gene Information

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Oxcarbazepine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Anticonvulsant, antineuralgic. Inhibits veratrine-induced transmitter release.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1483152

Oxcarbazepine, United States Pharmacopeia (USP) Reference Standard

Y0001549

Oxcarbazepine impurity mixture, European Pharmacopoeia (EP) Reference Standard

1483185

Oxcarbazepine Related Compound C, United States Pharmacopeia (USP) Reference Standard

1483200

Oxcarbazepine Related Compound E, United States Pharmacopeia (USP) Reference Standard

1483196

Oxcarbazepine Related Compound D, United States Pharmacopeia (USP) Reference Standard

1483174

Oxcarbazepine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1483163

Oxcarbazepine Related Compound A, United States Pharmacopeia (USP) Reference Standard

PHR2238

Oxcarbazepine Related Compound E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR3071

Oxcarbazepine Related Compound C, pharmaceutical secondary standard, certified reference material

PHR3294

Licarbazepine, pharmaceutical secondary standard, certified reference material

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Barbara R Sommer et al.
Expert opinion on drug safety, 6(2), 133-145 (2007-03-21)
Few controlled studies are available to guide the clinician in treating potentially assaultive elderly individuals with psychiatric disorders. Safety concerns limit the use of benzodiazepines and antipsychotic medications in the elderly individual, making anticonvulsants an attractive alternative. This paper reviews
A Vasudev et al.
The Cochrane database of systematic reviews, (1)(1), CD005171-CD005171 (2008-02-07)
Some studies have suggested that oxcarbazepine has a role in preventing episode recurrence in bipolar affective disorder. This review attempted to investigate the existing evidence from randomised controlled trials for its use in the maintenance treatment of this illness. To
Gaetano Zaccara et al.
Seizure, 22(7), 528-536 (2013-04-30)
Analysis of overall tolerability and neurological adverse effects (AEs) of eslicarbazepine acetate (ESL), lacosamide (LCM) and oxcarbazepine (OXC) from double-blind, placebo-controlled trials. Indirect comparisons of patients withdrawing because of AEs, and the incidence of some vestibulocerebellar AEs between these three
Wetid Pratoomsri et al.
Canadian journal of psychiatry. Revue canadienne de psychiatrie, 51(8), 540-545 (2006-08-29)
To review the data on the efficacy of oxcarbazepine (OXC) in bipolar disorder (BD) and to provide recommendations for clinicians on the use of this medication in treating BD. Using the terms oxcarbazepine and bipolar disorder, oxcarbazepine and mania, or
Penny Bring et al.
Clinical pharmacokinetics, 47(12), 767-778 (2008-11-26)
Oxcarbazepine, the 10-keto analogue of carbamazepine, is approved for the treatment of partial seizures or generalized tonic-clonic seizures. The primary metabolite of oxcarbazepine is monohydroxylated derivative (MHD). This review follows a decision-making algorithm to determine if therapeutic drug monitoring of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service